Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Public ClinicalTrials.gov record NCT05300048. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss
Study identification
- NCT ID
- NCT05300048
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Faeth Therapeutics
- Industry
- Enrollment
- 34 participants
Conditions and interventions
Interventions
- Insulin Suppressing Diet Other
- Nab paclitaxel Drug
- Serabelisib Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2022
- Primary completion
- Apr 29, 2025
- Completion
- Apr 29, 2025
- Last update posted
- Apr 29, 2026
2022 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35429 | — |
| Pacific Cancer Specialists | Anaheim | California | 92801 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Community Health Network, Inc. | Indianapolis | Indiana | 46250 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55902 | — |
| New Jersey Cancer Care, PA | Belleville | New Jersey | 07109 | — |
| Englewood Health | Englewood | New Jersey | 07631 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| East Carolina University | Greenville | North Carolina | 27858 | — |
| University of Pennsylvania Health System, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Baptist Hospitals of Southeast Texas | Beaumont | Texas | 77701 | — |
| Oncology Consultants, PA | Houston | Texas | 77030 | — |
| Lumi Research | Kingwood | Texas | 77339 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05300048, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05300048 live on ClinicalTrials.gov.